Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
no official package insert Clinical trial status / No completed Phase III trials in humans for TB-500 specifically Bulk drug substance status / Subject to ongoing FDA review for compounding eligibility DEA scheduling / TB-500 is not a controlled substance Key safety concern / No large-scale human safety data from randomized controlled trials Regulatory trend / FDA has increased scrutiny of peptide compounding since 2023 Parent molecule research / Thymosin beta-4 studied in wound healing and cardiac repair preclinical models TB-500 Has No FDA Approval TB-500 has never been submitted to or approved by the FDA through a New Drug Application (NDA) or Biologics License Application (BLA)
Injectable NAD and nicotinamide-riboside study Key Takeaway GHK-Cu vs NAD+ comparison
Simply resume normal dosing at your next scheduled administration
Peptide Dosing Safety Guidelines Getting the dose right is only half the equation
